Clinical Trial Update: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial update for AMG 910 in CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma; study status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric and Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AMG 910

Snippet

Sponsor: Amgen | Conditions: Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 1 | Status: TERMINATED | Results posted: 2024-01-25